BB Biotech AG Has $164.79 Million Position in Alexion Pharmaceuticals, Inc. (ALXN)

BB Biotech AG increased its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 10.2% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 1,354,428 shares of the biopharmaceutical company’s stock after acquiring an additional 125,000 shares during the quarter. Alexion Pharmaceuticals comprises 5.0% of BB Biotech AG’s investment portfolio, making the stock its 7th largest holding. BB Biotech AG owned approximately 0.61% of Alexion Pharmaceuticals worth $164,793,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. BlackRock Inc. grew its holdings in Alexion Pharmaceuticals by 2,689.8% during the 1st quarter. BlackRock Inc. now owns 18,628,080 shares of the biopharmaceutical company’s stock valued at $2,258,467,000 after buying an additional 17,960,356 shares in the last quarter. Bank of Montreal Can grew its holdings in Alexion Pharmaceuticals by 628.8% during the 2nd quarter. Bank of Montreal Can now owns 1,423,318 shares of the biopharmaceutical company’s stock valued at $173,174,000 after buying an additional 1,228,025 shares in the last quarter. TIAA CREF Investment Management LLC grew its holdings in Alexion Pharmaceuticals by 42.2% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 3,219,961 shares of the biopharmaceutical company’s stock valued at $391,773,000 after buying an additional 955,578 shares in the last quarter. Bessemer Group Inc. grew its holdings in Alexion Pharmaceuticals by 1,949,640.5% during the 2nd quarter. Bessemer Group Inc. now owns 721,404 shares of the biopharmaceutical company’s stock valued at $87,772,000 after buying an additional 721,367 shares in the last quarter. Finally, State Street Corp grew its holdings in Alexion Pharmaceuticals by 6.8% during the 1st quarter. State Street Corp now owns 11,298,685 shares of the biopharmaceutical company’s stock valued at $1,369,846,000 after buying an additional 718,756 shares in the last quarter. 94.17% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “BB Biotech AG Has $164.79 Million Position in Alexion Pharmaceuticals, Inc. (ALXN)” was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://ledgergazette.com/2017/09/22/bb-biotech-ag-has-164-79-million-position-in-alexion-pharmaceuticals-inc-alxn.html.

A number of research analysts have weighed in on ALXN shares. UBS AG reaffirmed a “buy” rating and set a $142.00 target price (up previously from $140.00) on shares of Alexion Pharmaceuticals in a report on Monday, June 26th. Deutsche Bank AG reduced their target price on Alexion Pharmaceuticals from $160.00 to $153.00 and set a “buy” rating for the company in a report on Thursday, May 25th. Morgan Stanley reaffirmed an “overweight” rating and set a $153.00 target price (up previously from $141.00) on shares of Alexion Pharmaceuticals in a report on Friday, July 28th. J P Morgan Chase & Co raised Alexion Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $163.00 to $175.00 in a report on Tuesday, September 5th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $182.00 target price (up previously from $170.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. They noted that the move was a valuation call. Five investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and three have given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $157.21.

Shares of Alexion Pharmaceuticals, Inc. (ALXN) traded down 0.78% during trading on Friday, reaching $141.80. The company’s stock had a trading volume of 193,276 shares. The company has a 50 day moving average of $139.14 and a 200-day moving average of $124.77. Alexion Pharmaceuticals, Inc. has a 12-month low of $96.18 and a 12-month high of $149.34. The stock has a market cap of $31.65 billion, a price-to-earnings ratio of 61.49 and a beta of 1.40.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.48. The business had revenue of $912.00 million during the quarter, compared to analyst estimates of $846.15 million. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The company’s revenue for the quarter was up 21.1% on a year-over-year basis. During the same period last year, the company earned $1.13 EPS. Analysts forecast that Alexion Pharmaceuticals, Inc. will post $5.60 EPS for the current year.

In other news, Director Ann M. Veneman sold 835 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total value of $121,751.35. Following the completion of the sale, the director now directly owns 5,480 shares of the company’s stock, valued at approximately $799,038.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Julie O’neill sold 11,160 shares of the firm’s stock in a transaction that occurred on Monday, August 28th. The shares were sold at an average price of $140.00, for a total value of $1,562,400.00. Following the completion of the sale, the executive vice president now directly owns 26,704 shares of the company’s stock, valued at $3,738,560. The disclosure for this sale can be found here. Insiders sold a total of 17,070 shares of company stock valued at $2,416,869 over the last ninety days. Corporate insiders own 4.35% of the company’s stock.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply